Evidence map›Paper›PMID 31425885›Full record

ArticleNew biotechnology2020

Improved protein expression in HEK293 cells by over-expressing miR-22 and knocking-out its target gene, HIPK1.

Sarah Inwood, Laura Abaandou, Michael Betenbaugh, Joseph Shiloach

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in New biotechnology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

  1. Cell Engineering for Increasing Production of Recombinant Proteins in Mammalian Cells.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026
    Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Sarah InwoodBiotechnology Core Laboratory NIDDK, NIH, Bethesda, Maryland, 20892, USA; Department of Chemical and Biomolecular Engineering Johns Hopkins University, Baltimore, Maryland, 21218, USA.
Laura AbaandouBiotechnology Core Laboratory NIDDK, NIH, Bethesda, Maryland, 20892, USA.
Michael BetenbaughDepartment of Chemical and Biomolecular Engineering Johns Hopkins University, Baltimore, Maryland, 21218, USA.
Joseph ShiloachBiotechnology Core Laboratory NIDDK, NIH, Bethesda, Maryland, 20892, USA. Electronic address: Josephs@niddk.nih.gov.
Core Laboratories (United States) · USJohns Hopkins University · US

Funding

Production and purification of biological compoundsZICDK015500 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI SHILOACH, JOSEPH · 2009 to 2022
$7.2M
Identification of genes related to spcific properties of mammalian cellsZIADK075080 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI SHILOACH, JOSEPH · 2012 to 2022
$5.0M
LARGE-SCALE PRODUCTION &PURIFICATION OF COMPOUNDS WITH BIOLOGICAL ACTIVITYZ01DK015500 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI SHILOACH, JOSEPH · 1986 to 2008
$568k
Intramural NIH HHS Z01 DK015500
6 · The paper itself

Abstract

Stable cell lines can continuously produce a recombinant protein without the need to repeatedly engineer the genome. In a previous study HIPK1, Homeodomain-interacting Protein Kinase 1, was found to be a target of the microRNA miR-22 that, when repressed, improved expression of both an intracellular and a secreted protein. In this report, HEK293 cells stably over-expressing miR-22 were compared with HEK293 with knockout of HIPK1, executed by CRISPR/Cas9, for their ability to improve recombinant protein expression. In this model case of luciferase, over-expression of miR-22 improved overall activity 2.4-fold while the HIPK1 knockout improved overall activity 4.7-fold.

Indexed as

Gene ExpressionGene Knockout TechniquesHEK293 CellsHumansMicroRNAsProtein BiosynthesisProtein Serine-Threonine KinasesHIPK1 protein, humanMicroRNAsMIRN22 microRNA, humanProtein Serine-Threonine KinasesCRISPR/Cas9HIPK1miR-22Protein expressionStable

Identifiers

PMID31425885
PMCPMC6759407
OpenAlexW2967845111

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.